LOU064 BTK Inhibitor Selective B Cell Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple sclerosis (MS) using BTK inhibitors face challenges with adverse events and uncertain long-term efficacy, necessitating the development of safer and more effective therapies that can sustainably control pathogenic B cells without compromising immunoglobulin levels.
Innovation Solution
The administration of LOU064, a potent and highly selective, irreversible covalent BTK inhibitor, which achieves sustained pharmacodynamic effects with minimal kinase off-target binding, thereby reducing B cell activation and inflammation in MS, while maintaining safety and tolerability profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If B-cell-depleting agents are administered long-term, then MS disease activity is reduced, but key immune system functions are impaired
Solution Approach 1:
The patent segments the B cell population by targeting specific subsets (naive B cells, memory B cells, plasmablasts) with different DMTs, allowing selective depletion or modulation of pathogenic subsets while preserving protective B cell functions and immunoglobulin production
Solution Approach 2:
The patent changes the mechanism of action from direct B cell depletion to modulating B cell function through cytokine shifts, increased B-regs, decreased MHC class II expression, and blocked trafficking, thereby achieving disease control while maintaining immune competence
2Object-generated harmful factors
If BTK inhibitors are used to control pathogenic B cells, then B cell activation is reduced, but immunoglobulin levels may be compromised
Solution Approach 1:
The patent applies partial inhibition of BTK to achieve sufficient suppression of pathogenic B cell activation while maintaining enough B cell function for normal immunoglobulin production, avoiding complete blockade that would compromise immune defense
Solution Approach 2:
The patent creates different functional states in different B cell compartments by using BTK inhibitors that preferentially affect activated pathogenic B cells while sparing naive and memory B cells that are needed for maintaining immunoglobulin levels
Data Source
AI summary
The invention concerns method of treating multiple sclerosis (MS) by administering a therapeutically effective dose of LOU064 or a pharmaceutically acceptable salt thereof.